title: Alternative to ganglionic blockade with anticholinergic and alpha-2 receptor agents.
abstract: The ganglionic blocking agent trimethaphan (TMP) is no longer produced. Therefore, a need exists for alternative pharmacological approaches to investigate baroreflex control of the circulation. The aim of the present study was to examine baroreflex-mediated cardiovascular responses during the administration of a muscarinic receptor antagonist (glycopyrrolate; GLY: ) and a selective alpha-2 receptor agonist (dexmedetomidine; DEX: ) and to compare responses to ganglionic blockade with TMP. We hypothesized that combined GLY-: DEX: would inhibit the baroreflex similar to TMP. Ten volunteers participated in two study days and were instrumented with pulse oximeter, nasal cannula, ECG, continuous blood pressure monitoring (Finapres), and I.V. catheter for drug infusions. Each study day consisted of a control condition followed by either combined GLY: -DEX: or TMP on alternating days. A Valsalva maneuver was performed under each condition with every subject and six subjects received bolus phenylephrine (25 mug) during GLY: -DEX: and TMP. Combined GLY: -DEX: increased (P < 0.05) blood pressure (99 +/- 4 mmHg) and heart rate (99 +/- 3 bpm) relative to control condition (BP: 90 +/- 2 mmHg; HR: 64 +/- 3 bpm) and TMP infusion decreased (P < 0.05) blood pressure (79 +/- 3 mmHg) while increasing heart rate (88 +/- 3 bpm). Valsalva maneuver elicited a persistent drop in arterial pressure (no phase IIb recovery) with the absence of a phase IV overshoot during both GLY: -DEX: and TMP conditions. Phenylephrine increased systolic pressure 34 +/- 4 mmHg under GLY: -DEX: and 23 +/- 3 mmHg with TMP (P < 0.05). Heart rate only decreased 1 +/- 2 bpm during GLY: -DEX: and 1 +/- 1 bpm with TMP. Taken together, our results suggest that GLY: -DEX: is a reasonable alternative to TMP for baroreflex inhibition.
authors.affiliation: Dept of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Brad W
authors.initials: BW
authors.lastname: Wilkins
authors.forename: Christiane
authors.initials: C
authors.lastname: Hesse
authors.forename: Hans P
authors.initials: HP
authors.lastname: Sviggum
authors.forename: Wayne T
authors.initials: WT
authors.lastname: Nicholson
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Moyer
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Joyner
authors.forename: John H
authors.initials: JH
authors.lastname: Eisenach
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D018680:Cholinergic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D020927:Dexmedetomidine / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D045888:Ganglion Cysts / Q000188:drug therapy*; D006024:Glycopyrrolate / Q000627:therapeutic use; D006262:Health; D006801:Humans; D008297:Male; D010656:Phenylephrine / Q000494:pharmacology* / Q000627:therapeutic use; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D014294:Trimethaphan / Q000627:therapeutic use; D014636:Valsalva Maneuver
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D018680:Cholinergic Antagonists; D018341:Receptors, Adrenergic, alpha-2; D010656:Phenylephrine; D020927:Dexmedetomidine; D014294:Trimethaphan; D006024:Glycopyrrolate